InVivo Therapeutics to Present at the Inaugural Marcum MicroCap Conference on June 20th in NYC

Published on Monday, 18 June 2012 06:04 Written by TradersHuddle Staff

CAMBRIDGE, Mass.-( Business Wire )-

InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that Frank Reynolds, InVivo Therapeutics Chief Executive Officer, will present at the Marcum MicroCap Conference on June 20^th in New York City at the Roosevelt Hotel. The event is held by Marcum LLP, one of the top ten auditors of U.S. public companies.

Presentation Details

• Date: Wednesday, June 20, 2012
• Time: 11:00 am
• Location: The Roosevelt Hotel, 45 East 45^th Street, New York, NY

Presenting on behalf of InVivo Therapeutics will be Frank Reynolds, CEO. A live audio webcast of this presentation will be available at http://execvid.com/marcum-microcap-conference-2012.

The Marcum MicroCap conference is designed for investors interested in the micro-cap arena, and is expected to gather over 500 participants, including institutional investors, mutual funds, hedge funds, wealth managers, and family offices. The conference will also feature panels on subjects highly relevant to small-cap corporate finance. The event is free to attend for qualified investors and the company will make a formal presentation and be available for one-on-ones.

For full event details and registration information, please click here.

About Marcum LLP

Marcum LLP is one of the largest independent public accounting and advisory services firms in the nation. Ranked among the top firms in the nation, Marcum offers the resources of more than 1,100 professionals, including more than 150 partners, in 23 offices throughout New York, New Jersey, Massachusetts, Connecticut, Pennsylvania, California, Florida, Grand Cayman, China and Hong Kong. The Firm's presence runs deep with full service offices strategically located in major business markets. Marcum is a member of the Marcum Group, the gateway to a group of organizations that provide a variety of professional services including accounting and advisory, technology solutions, recruiting, and wealth management. These organizations include Marcum LLP; Marcum Technology LLC; MarcumBuchanan Associates LLC; Marcum Search LLC; Marcum Financial Services LLC; Marcum Cronus Partners LLC; Marcum Bernstein and Pinchuk LLP; and Marcum Healthcare LLC.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, Mass. For more details, visit www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to sell additional shares of common stock and warrants to purchase common stock at additional closings, the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our Form 10-K and Form 10-Qs and our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

Investor Relations Contact:Investor Awareness, Inc.Tony Schor, This e-mail address is being protected from spambots. You need JavaScript enabled to view it.